Use of physiologically based kinetic modeling-facilitated reverse dosimetry of in vitro toxicity data for prediction of in vivo developmental toxicity of tebuconazole in rats
A PBK model was developed that describes tebuconazole kinetics in rats. It was used to predict developmental toxicity based on in vitro toxicity data. The predicted in vivo dose-response data were used to determine a BMDL10. The BMDL10 differed only 3-fold from the reported NOAEL values. BMDL10 value from predicted toxicity data may serve as a POD for risk assessment.